APA (7th ed.) Citation

M, B., M, T., S, Z., V, D., EY, C., MG, T., . . . SV, S. (2024). Efforts to Better Characterize "Antiphospholipid Antibody Nephropathy" for the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria: Renal Pathology Subcommittee Report. The Journal of rheumatology, 51(2), 150. https://doi.org/10.3899/jrheum.2022-1200

Chicago Style (17th ed.) Citation

M, Barbhaiya, Taghavi M, Zuily S, Domingues V, Chock EY, Tektonidou MG, Erkan D, and Seshan SV. "Efforts to Better Characterize "Antiphospholipid Antibody Nephropathy" for the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria: Renal Pathology Subcommittee Report." The Journal of Rheumatology 51, no. 2 (2024): 150. https://doi.org/10.3899/jrheum.2022-1200.

MLA (9th ed.) Citation

M, Barbhaiya, et al. "Efforts to Better Characterize "Antiphospholipid Antibody Nephropathy" for the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria: Renal Pathology Subcommittee Report." The Journal of Rheumatology, vol. 51, no. 2, 2024, p. 150, https://doi.org/10.3899/jrheum.2022-1200.